



# Biotech Daily

Wednesday April 10, 2024

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: IMPEDIMED UP 9%; SYNTARA DOWN 10.5%**
- \* **IMMURON RECORD 9-MONTH TRAVELAN SALES UP 154% TO \$3.6m**
- \* **ANTERIS RAISES \$23m FROM UNNAMED INVESTOR(S)**
- \* **SOMNOMED INSTO RIGHTS RAISE \$7.5m; \$17m RETAIL RIGHTS TO GO**
- \* **GOODBYE REGENEUS, HELLO CAMBIUM BIO**
- \* **SYNTARA RECRUITS HALF OF SNT-5505 BONE CANCER TRIAL**
- \* **ARGENICA DOSES 1st STROKE COHORT; 'CAPITAL RAISING' HALT**
- \* **NEUROTECH TREATS LAST NTI-164 MARIJUANA AUTISM PATIENT**
- \* **IMRICOR WINS FRENCH VISION-MR TRIAL APPROVAL**
- \* **PHARMAUST FINAL MONEPANTEL MND EXTENSION STUDY APPROVED**
- \* **EMYRIA OPENS EMPAX MDMA-THERAPY CENTRE**
- \* **MICROBA RECEIVES \$6.1m FEDERAL R&D TAX INCENTIVE**
- \* **ARCHER DILUTED TO 10% OF CHEMX MATERIALS**
- \* **HERAMED: ANOUSHKA GUNGADIN CEO, CAMERON JONES CFO, CO SEC**

## MARKET REPORT

The Australian stock market was up 0.31 percent on Wednesday April 10, 2024, with the ASX200 up 24.3 points to 7,848.5 points. Eighteen of the Biotech Daily Top 40 stocks were up, 13 were down and nine traded unchanged.

Impedimed was the best, up 0.8 cents or 8.9 percent to 9.8 cents, with 2.1 million shares traded. Dimerix climbed seven percent; Curvebeam was up 5.6 percent; Micro-X and Nanosonics improved more than four percent; Actinogen, Atomo, Nova Eye and Starpharma were up more than three percent; Cynata, Emvision, Neuren and Resmed rose more than two percent; Clarity, CSL and Resonance were up more than one percent; with Clinuvel, Cyclopharm and Polynovo up by less than one percent.

Syntara led the falls, down 0.2 cents or 10.5 percent to 1.7 cents, with 1.4 million shares traded. Imugene and Opthea fell more than four percent; Immutep, Mesoblast and Orthocell lost more than three percent; 4D Medical, Avita, Next Science and Proteomics were down one percent or more; with Cochlear, Medical Developments, Pro Medicus and Telix down by less than one percent.

## IMMURON

Immuron says sales of its Travelan for travellers' diarrhoea for the nine-months to March 31, 2024 were up 154 percent to \$3.6 million, compared to the prior period.

Last year, Immuron said revenue from contracts with customers for the year to June 30, 2023 was up 135.8 percent from \$765,193 in 2022 to \$1,804,705, primarily due to the sales recovery of Travelan in Australia, the US and North American markets, and that it expected revenues to "continue to increase in the future".

Today the company said that sales for the three months to March 31, 2024 were \$1.3 million, which was up 51 percent on the previous corresponding period.

Immuron said Australian sales increased 250 percent in the nine months to \$2.7 million, with US sales up 35 percent to \$800,000.

Immuron chief commercial officer Flavio Palumbo said the company continued "to be excited by the strong sales results on Travelan".

"Immuron's investment to drive awareness of the Travelan brand has seen continued strong sales results in Australia," Mr Palumbo said.

"We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring and summer vacation peak period," Mr Palumbo said.

Immuron was up 1.5 cents or 13.6 percent to 12.5 cents with 4.6 million shares traded.

## ANTERIS TECHNOLOGIES

Anteris says it has raised \$23 million from an unnamed investor(s) to fund preparations for a US Food and Drug Administration pivotal study of its Duravr transcatheter heart valve.

Anteris said that the funds raised in the \$23.00 a share placement would be used to gain FDA regulatory clearance as well as for its initiatives, valve-in-valve trials and general working capital.

Anteris was up 25 cents or 1.1 percent to \$23.25.

## SOMNOMED

Somnomed says the institutional part of its one-for-1.01 entitlement offer at 21.0 cents a share has raised \$7.5 million, with an up-to about \$16.8 million retail offer to follow.

Yesterday, Somnomed said it hoped to raise \$22.6 million at 21.0 cents in a pro-rata, non-renounceable, fully-underwritten, one-for-1.01 entitlement offer (BD: Apr 9, 2024).

Today, the company said the institutional component of the offer had a 70.6 percent take-up rate, raising \$5.8 million, with the remaining \$1.7 million shortfall placed to "certain new and existing institutional investors".

Somnomed said no shortfall shares were allocated to the sub-underwriter TDM Growth Partners Pty Ltd.

The company said that the further retail component of the offer would raise up-to \$16.8 million from shareholders on the record date of April 11, open on April 16 and close on May 7, 2024.

Somnomed fell 18 cents or 46.75 percent to 20.5 cents with 1.1 million shares traded.

## CAMBIUM BIO (FORMERLY REGENEUS)

Cambium says it has formally changed its name from Regeneus and changed its ASX ticker code to CMB (BD: Apr 8, 2024).

Cambium was up 0.2 cents or 16.7 percent to 1.4 cents.

### SYNTARA (FORMERLY PHARMAXIS)

Syntara says it has recruited eight of 15 patients in its phase II trial of SNT-5505 with ruxolitinib for bone marrow cancer, with interim results expected in December.

Last year, Syntara said it had dosed the first of up-to 15 patients in the trial of SNT-5505 with the Janus kinase inhibitor ruxolitinib for myelofibrosis (BD: Dec 13, 2023).

Today, the company said the open-label study began in December 2023 with the eighth patient dosed earlier this week and it expected to complete recruitment by July 2024.

Syntara said interim data was expected to be used to discuss pivotal study design with the US Food and Drug Administration in 2025, with the 12-month data set to be “available by mid-2025”.

Syntara chief executive officer Gary Phillips said the company was “pleased with the progression of recruitment in this trial as we observe the impact SNT-5505 can have in combination with the approved standard-of-care ruxolitinib”.

Syntara fell 0.2 cents or 10.5 percent to 1.7 cents with 1.4 million shares traded.

### ARGENICA THERAPEUTICS

Argenica says it has dosed the first five-patient cohort in its up-to 92-patient, phase II study of ARG-007 for acute ischaemic stroke, with no adverse events reported.

In February, Argenica said it had manufactured ARG-007 for its 92-patient, double-blinded, randomized, placebo-controlled, single-dose phase II trial for acute ischaemic stroke, with dosing expected to begin in March (BD: Feb 12, 2024).

Today, the company said the patients presented at the Royal Melbourne Hospital and Brisbane’s Princess Alexandra Hospital, with three of 10 hospital sites activated to begin patient dosing, and the remaining sites to be “activated imminently”.

Argenica said the first cohort had been reviewed by the data safety monitoring board, with further reviews scheduled after dosing 23, 46, 69 and all 92 patients.

Argenica managing-director Dr Liz Dallimore said “dosing of the first safety cohort after less than two weeks is a testament to the dedication of the clinical trial teams working in the emergency departments of our trial sites”.

Separately, the company requested a trading halt “regarding a capital raising”, with trading to resume on April 12, 2024, or on an earlier announcement.

Argenica last traded at 63.5 cents.

### NEUROTECH INTERNATIONAL

Neurotech says it has treated all 54 pediatric patients in its eight-week phase II/III clinical trial of the marijuana-based NTI-164 for autism spectrum disorder.

Last year, Neurotech said it completed recruitment for the trial of its marijuana-based NTI164 for children with autism spectrum disorder (BD: Dec 19, 2023).

Today, the company said all patients in the trial had completed eight weeks of daily NTI-164 treatment at the Monash Medical Centre, with results expected by July 2024.

Neurotech executive director Dr Thomas Duthy said the results would inform “discussions with the Therapeutic Goods Administration to understand our pathway to market approval in Australia as our first market opportunity”.

“With the explosion in autism-associated costs under the Australian National Disability Insurance Scheme, there is an urgent need for new enabling treatments like NTI164, which has been shown to significantly improve adaptive behaviors and socialization and improve these children’s quality of life in an earlier clinical trial,” Dr Duthy said.

Neurotech was up half a cent or five percent to 10.5 cents.

### IMRICOR MEDICAL SYSTEMS

Imricor says it has French regulatory authority approval to begin its up-to 91-patient trial of Vision-MR cardiac ablation catheter for atrial flutter ablation at a site in Paris.

Last month, Imricor said the Cardiovascular Institute of South Paris, or the Institut Cardiovasculaire Paris Sud, had approved the trial, but that it still required National Agency for Medicines and Health Products approval (BD: Mar 11, 2024).

Imricor was up five cents or 10 percent to 55 cents.

### PHARMAUST

Pharmaust says it has approval to enrol the final three of 12 patients in its extension study of monepantel for motor neuron disease (MND) at Macquarie University.

In February, Pharmaust said it had dosed the first of up-to 12 patients in its open-label, phase I, 12-month extension study of monepantel for motor neuron disease and, or amyotrophic lateral sclerosis (BD: Feb 14, 2024).

Pharmaust was up 1.5 cents or 4.2 percent to 37 cents with 1.1 million shares traded.

### EMYRIA

Emyria says it has opened the Empax Centre with Perth's Pax Centre for the delivery and evaluation of 3,4 methylene-dioxy-meth-amphetamine (MDMA)-assisted therapy.

Emyria said the centre was expected to "substantially increase the company's care delivery and research revenues as well as directly support [its] ... innovation pipeline", with operational profitability expected by the end of the year.

The company said the "first Empax Centre is aiming at achieving operational profitability ... [this year] with potential for national and global scalability via further site expansion".

Emyria was unchanged at 6.2 cents.

### MICROBA LIFE SCIENCES

Microba says it has received \$6,089,165 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.

Microba said the incentive related to research and development expenditure for the year to June 30, 2023.

The company said it had a separate advanced overseas finding from Ausindustry, which would cover eligible overseas expenditure until June 30, 2025.

Microba fell two cents or 10 percent to 18 cents.

### ARCHER MATERIALS

Archer says its 11,571,119 share-holding in Perth's Chemx Materials has been diluted from 12.75 percent to 9.87 percent following the company's recent capital raise.

Archer was up 2.5 cents or 4.95 percent to 53 cents.

## HERAMED

Heramed says it has appointed Anoushka Gungadin chief executive officer, Cameron Jones chief financial officer, with chair Dr Ron Weinberger stepping down from executive. Heramed said Ms Gungadin was on the council of Deakin University and had previously been founding chief executive officer of the Australia India Chamber of Commerce and consultant for Mondelez, l'Oreal, Bank of Indonesia, Reliance and Rhipe-Crayon. According to her LinkedIn profile, Ms Gungadin held a Bachelor of Science from the University of Mauritius and a Master of Business Administration from the University of Melbourne.

Heramed said Bio101 Financial Advisory managing-director Mr Jones had replaced the Jonathan Hart.

According to his LinkedIn profile, Mr Jones held a Bachelor of Accounting from Melbourne's Monash University.

The company said Dr Weinberger had stepped down from his executive role and would remain a director "in the short term until a suitable candidate is appointed".

Heramed was in a suspension and last traded at 1.7 cents.